Ukr.Biochem.J. 2013; Volume 85, Issue 4, Jul-Aug, pp. 111-118


Development and optimization of the methods for determining activity of plasminogen activator inhibitor-1 in plasma

Y. M. Roka-Moya, D. D. Zhernossekov, A. S. Kondratyuk, T. V. Grinenko

Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine, Kyiv;

The activity and content of plasminogen activator inhibitor-1 (PAI-1) are important indicators of pathological processes, because its content in plasma increases at acute myocardium infarction, tumor, diabetes mellitus, etc. The present work is dedicated to the development and optimization of the methods of PAI-1 activity definition, which can be used in clinical practice. We have proposed the modification of the method COATEST PAI with the usage of chromogenic substrate S2251. According to our modification, the cyanogen bromide fragments of human fibrinogen have been changed into bovine desAB-fibrin. We have also developed the method with the usage of fibrin films. In this method fibrin is used as a stimulator of activation reaction and as a substrate at the same time. Using fibrin, the native substrate of plasmin, we provide high specificity of the reaction and exclude the cross-reaction with other plasma enzymes.

Keywords: , , , ,


  1. Horrevoets AJ. Plasminogen activator inhibitor 1 (PAI-1): in vitro activities and clinical relevance. Br J Haematol. 2004 Apr;125(1):12-23. Review. PubMedCrossRef
  2. Zhernossekov DD, Zolotareva EN, Kondratuk AS. Structural and functional peculiarities of plasminogen activator inhibitor PAI-1. Biopolym Cell. 2010;26(4):255-264. CrossRef
  3. Knudsen EC, Seljeflot I, Abdelnoor M, Eritsland J, Mangschau A, Müller C, Arnesen H, Andersen GØ. Elevated levels of PAI-1 activity and t-PA antigen are associated with newly diagnosed abnormal glucose regulation in patients with ST-elevation myocardial infarction. J Thromb Haemost. 2011 Aug;9(8):1468-74. PubMed, CrossRef
  4. von Eyben FE, Mouritsen E, Holm J, Montvilas P, Dimcevski G, Suciu G, Rasmussen IH, Kristensen LL, von Eyben R. Plasminogen activator inhibitor 1 activity and other coronary risk factors. Clin Appl Thromb Hemost. 2005 Jan;11(1):55-61. PubMed, CrossRef
  5. Brazionis L, Rowley K, Jenkins A, Itsiopoulos C, O’Dea K. Plasminogen activator inhibitor-1 activity in type 2 diabetes: a different relationship with coronary heart disease and diabetic retinopathy. Arterioscler Thromb Vasc Biol. 2008 Apr;28(4):786-91. PubMed, CrossRef
  6. Agren A, Kolmert T, Wiman B, Schulman S. Low PAI-1 activity in relation to the risk for perioperative bleeding complications in transurethral resection of the prostate. Thromb Res. 2007;119(6):715-21. Epub 2006 Aug 14. PubMed, CrossRef
  7. Varetskaia TV, Loseva AL, Yatsenko VI. On the determination of thrombin activity. Ukr Biokhim Zhurn. 1961;33:657-66. Ukrainian. PubMed
  8. Varetskaia TV. Preparation of a fibrin monomer and studies on some of its properties. Ukr Biokhim Zhurn. 1965;37(2):194-206. Ukrainian. PubMed
  9. Wallén P, Wiman B. Characterization of human plasminogen. I. On the relationship between different molecular forms of plasminogen demonstrated in plasma and found in purified preparations. Biochim Biophys Acta. 1970 Oct 20;221(1):20-30. PubMed, CrossRef
  10. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680-5. PubMed, CrossRef
  11. Mukherjee M, Sembhi K, Kakkar VV. Interference of an activity assay of tissue-type plasminogen activator in human plasma by endogenous factors. Blood Coagul Fibrinolysis. 1996 Jun;7(4):491-6. PubMed
  12. Kondratiuk AS, Yusova OI, Grynenko TV. Identification of activity of tissue plasminogen activator in blood plasma. Lab Diagnost. 2011;3(57):3-9.
  13. Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem. 1982 Mar 25;257(6):2912-9. PubMed

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.